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Abstract 
Alzheimer’s disease (AD) is a multifactorial syndrome resulting in profound misery and poses a 
substantial burden on human health, economy, and society throughout the world. Based on the 
numerous AD-related targets in the disease network, multi-target design strategy is a crucial 
direction to seek for enhanced therapy, and multi-target drugs have the ability to regulate more 
targets than single-target drugs, affecting the disease network with more potency. Herein, we 
highlight nine major targets associated with AD, which are acetylcholine esterase (AChE), 
beta-site amyloid precursor protein cleaving enzyme 1 (β-secretase, BACE-1), glycogen synthase 
kinase 3 beta (GSK-3β), monoamine oxidases (MAOs), metal ions in the brain, 
N-methyl-D-aspartate (NMDA) receptor, 5-hydroxytryptamine (5-HT) receptors, the third subtype 
of histamine receptor (H3 receptor), and phosphodiesterases (PDEs), and their respective 
relationship to the disease network. Furthermore, eleven multi-target design strategies classified 
by the involvement of AChE and related promising compounds for improved therapy of AD in 
recent years are described based on the nine major targets. 
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ACh    Acetylcholine  
AChE   Acetylcholine esterase 
AChEI       AChE inhibitor 
AD      Alzheimer’s disease  
APP    Amyloid precursor protein 
Aβ    beta-amyloid  
BACE-1     beta-site amyloid precursor protein cleaving enzyme 1  
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BBB     Blood-brain barrier  
BChE     Butyrylcholinesterase 
cAMP   Cyclic adenosine monophosphate  
cGMP    Cyclic guanosine monophosphate 
ChE    Cholinesterase  
CNS     Central nervous system 
COX   Cyclooxygenase 
CREB    cAMP response element-binding protein 
EC50     Concentration for 50% of maximal effect 
ED    Erectile dysfunction 
Gly    Glycine 
GSK-3β     Glycogen synthase kinase 3 beta 
HT      Hydroxytryptamine 
IC50    Half maximal inhibitory concentration 
Ki     Inhibition constant 
LOX   Lipoxygenase  
MAO         Monoamine oxidase 
MCI    Mild cognitive impairment 
MD    Myotonic dystrophy 
MMSE   Mini-Mental State Examination  
MTDL    Multi-target-directed ligand  
NCE      New chemical entity 
NFT    Neurofibrillary tangle  
NMDA    N-methyl-D-aspartate  
NO/sGC/cGMP  The nitric oxide/soluble guanylyl cyclase/cGMP 
NQO1   NAD(P)H:quinone oxidoreductase 1  
ORAC     Oxygen radical absorbance capacity 
PAMPA     The parallel artificial membrane permeation assay  
PD    Parkinson disease 
PDE      Phosphodiesterase 
ROS   Reactive oxygen species  
sAPP-α   Soluble amyloid precursor protein α  
SGZ    Subgranular zone  
SSRI   Selective serotonin reuptake inhibitor  
 
1. Introduction 
  AD is an progressive neurodegenerative disorder associated with the appearance of extracellular 
senile or neuritic plaques and intracellular neurofibrillary tangles in the brain [1] that induce 
memory loss and cognition impairment, causing enormous suffering to individuals, families, and 
society [2]. AD was first reported by Alois Alzheimer in 1907 [3] and is now deemed by World 
Health Organization as the most common cause of dementia, with approximately 47 million 
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patients worldwide in 2018, and is estimated to affect 75 million people by 2030 and 140 million 
people by 2050 globally [4]. The nebulous and complicated pathogenesis of AD makes it difficult 
to develop new drugs, and also leads to failure of many promising drug candidates when tested in 
clinical trials with the result of unpredictable clinical manifestations. Despite these challenges, 
research of AD is still a hot topic, and the efforts and attempts of scientific groups worldwide are 
continuing, with the aim of finding an effective treatment [5]. 
Currently, exploration of AD has led to the discovery of many primary targets that influence 
generation and exacerbation of the disease, such as AChE, BACE-1, GSK-3β, MAOs, metal ions 
in the brain, NMDA receptor, 5-HT receptors, H3 receptor, and PDEs (Figure 1). And lots of 
potent and effective compounds for the treatment of AD are discovered based on these targets, 
among which donepezil (1), galantamine (2), rivastigmine (3), and memantine (14) (Table 1) 
(Figure 2) are the only four drugs approved by the FDA for the treatment of AD. And all of them 
are single-target drugs that can notably improve the conditions of patients in cognition 
deterioration and memory loss, but these drugs cannot completely cure the disease. It is a unique 
and intricate feature of AD that relevant targets in different cell signaling pathways can interact 
with each other and form a disease network, and this results in a poor curative effect of single- 
 
 
Figure 1. Concise relationships between AD and nine major targets, and eleven multi-target design strategies 





target drugs. Based on the complicated pathogenesis of AD and the imperfect single-target drugs, 
multi-target strategies are becoming more and more popular for potential treatment of AD because 
several targets associated with AD could be affected by one multi-target drug, which can have a 
synergistic effect on the disease network, leading to better improvement on memory and cognition. 
Therefore, multi-target design strategy for AD therapy is an important direction in current research 
compared with single-target drugs, and multi-target drugs will likely be more pivotal and effective 
in regulating disease progression. 
 
2. Multi-target strategies involving AChE 
Nine related targets in AD are presented in this section, which are AChE, BACE-1, GSK-3β, 
MAOs, metal ions in the brain, NMDA receptor, 5-HT receptors, H3 receptor, and PDEs. These 
nine targets and their respective signaling pathways could influence the disease progression by 
themselves and interactions among them, also resulting in the complicated and unclear disease 
network of AD. Among them, AChE is the most pivotal target of the well-known AD network, and 
multi-target drugs are designed to involve this target to increase the availability and decrease the 
failure risk of new chemical entities (NCEs). In short, AChE is the most popular target in 
AD-related targets and multi-target design strategy involving AChE is the most popular strategy in 
AD-related multi-target strategies. In this section, eight multi-target strategies involving AChE and 
related targets are reviewed (Figure 1). 
2.1.1. AChE 
The cholinergic hypothesis, a significant guidance orientation of AD, was first reported by 
Davies and Maloney in 1976 [6], states that the reduction of acetylcholine (ACh) in presynaptic 
cholinergic terminals of the hippocampus and the neocortex regions caused by degeneration of 
cholinergic neurons of basal forebrain nuclei plays a key role in AD pathology, and the conclusive 
treatment is to up-regulate the ACh concentration in the synaptic cleft [7]. ACh in the synaptic 
cleft is secreted by synaptic vesicles to activate muscarinic and nicotinic receptors and is 
immediately decomposed to choline and acetate [8] by AChE under normal physiological 
conditions. AChE is a highly kinetically efficient enzyme, and each AChE molecule can hydrolyze 
5000 ACh molecules per second [9]. Butyrylcholinesterase (BChE) can also hydrolyze ACh, and 
its levels progressively rise in advancing AD, while AChE activity remains unchanged or declines 
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[10]. BChE is becoming an interesting target because selective BChE inhibitors have displayed 
amyloid-lowering activity which is a useful effect to improve dementia condition [11]. Highly 
selective BChE inhibitors or dual AChE and BChE inhibitors represent another new potential 
approach for AD treatment; however, this multi-target strategy is not discussed in this article  
 
 
Figure 2. Related single-target drugs that are approved or in clinical trials for the treatment of AD. Red refers to 




because of the unclear theoretical basis of BChE and the close relationship between the two targets 
[12]. 
Inhibition of AChE activity to prevent degradation of ACh in synapses is the most primary 
method in medicinal chemistry, which makes AChE a vital target and leads the inhibition activity 
of AChE to be a fundamental evaluation criterion. The present clinical drugs approved by the FDA 
are principally AChE inhibitors (AChEIs), such as donepezil (1), galantamine (2), and 
rivastigmine (3) [13] (Table 1) (Figure 2), which can notably slow down memory loss and improve 
the cognition function of patients, while dementia cannot be prevented or completely cured by 
them [14]. Tacrine (4) (Figure 2) was approved in 1993 as the first AChEI for AD treatment and 
was withdrawn shortly after due to liver toxicity [2], but its structure is still important for the new 
drug design. Donepezil (1) (Figure 2) of Eisai and Pfizer, the top-selling AChEI drug worldwide 
among AD-related clinical drugs, was approved in 1997 for the treatment of mild-to-moderate AD, 
and was approved in 2014 for additional treatment of Lewy body dementia. Donepezil (1) is 
available as disintegrating tablets or oral solutions to be administered at a dose of 5-10 mg once a 
day due to its long half-life, with a starting dose of 5 mg/day. Donepezil (1) is a safe and well 
tolerated drug based on current clinical evidence, it can improve cognition and shows clinical 
amelioration in overall functioning even for patients with severe AD [14]. Tacrine (4) and 
donepezil (1) are still subjected to various modifications by research groups [15], and are often 
used as positive controls in enzyme activity tests in vitro and in pharmacological experiments with 
AD-related animal models in vivo to test the AChE inhibitory potency and safety of NCEs. The 
cholinergic hypothesis and approved drugs make AChE and AChEIs a high profile in AD field, 
lead single-target strategy aiming at AChE and multi-target strategy involving AChE to become 
common thoughts in new drug design for the potential treatment of AD. 
2.1.2. BACE-1 
The amyloid hypothesis, a currently popular theoretical foundation first outlined by Hardy and 
Higgins in 1992 [16], states that the production, oligomerization and self-aggregation of 
beta-amyloid (Aβ) cause synaptic dysfunction and senile plaques which is the typical hallmark of 
AD [17]. The degradation of major amyloid precursor protein (APP) occurs through a two-step 
proteolysis reaction catalyzed by α-secretase and γ-secretase with no physical damage [18], while 
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a small proportion of APP is degraded by β-secretase (BACE-1) and γ-secretase to generate Aβ 
which is composed of 37-49 amino acid residues and mainly shown as Aβ40 and Aβ42 peptides [19]. 
Aβ40 is the more common metabolite and may actually be anti-amyloidogenic, whereas Aβ42 and 
longer peptides are highly self-aggregating and lead to profound Aβ deposition [20]. 
 
Table1. Fundamental information regarding four drugs which have been approved by the FDA for the treatment of 
AD 
Drug Donepezil (1) Galantamine (2) Rivastigmine (3) Memantine (14) 
Salt type Hydrochloride Hydrobromide Tartrate Hydrochloride 
Launch year for 
AD 
1997 1995 1997 2002 
Brand name Aricept Reminyl Exelon Ebixa 
Indication of AD Mild to moderate Mild to moderate Mild to moderate Moderate to severe 











Half-life [1] 70 h 7-8 h 1 h 60-100 h 
Metabolism [14] 
CYP2D6 and 
CYP3A4 in liver 
CYP2D6 and 
CYP3A4 in liver 
AChE Kidney 
Given with food Irrelevant Recommended Yes Irrelevant 
Clinically efficient 
dose 
5-10 mg/day 16-24 mg/day 6-12 mg/day 20 mg/day 
 
Despite continuing arguments for the amyloid hypothesis [18], the growing consensus is that 
anti-amyloid drugs will be most effective in the early AD process [21]. Obviously, BACE-1 is the 
most suitable target to decrease Aβ production in the APP metabolic pathway by inhibiting its 
activity, and mice with BACE-1 deficiency showed a healthy and fertile clinical phenotype with 
abolished Aβ production in the brain [22], making BACE-1 a popular target and its inhibitors an 
attractive therapeutic strategy. The clinical situation of BACE-1 inhibitors is cruel (Figure 2). The 
drug verubecestat (5) of Merck in Phase III was discontinued in February 2017 due to lack of 
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efficacy [23, 24]. The Phase II/III drug atabecestat (6) of Johnson & Johnson was discontinued in 
May 2018 for the increase of hepatic enzyme, and the Phase III drug lanabecestat (7) of Eli Lilly 
and AstraZeneca was discontinued in June 2018 because no curative endpoint was achieved. The 
optimistic cases of BACE-1 inhibitors are that the drug LY3202626 (structure not disclosed) from 
Eli Lilly is in Phase II clinical trials, the drug elenbecestat (8) from Biogen and Eisai is in Phase 
III clinical trials [25], and the drug umibecestat (9) from Novartis and Amgen is in Phase III 
clinical trials. 
2.1.3. AChE and BACE-1 multi-target strategy 
Design of multi-target NCEs based on AChEI drugs, such as donepezil (1) and tacrine (4), is 
popular because the scaffolds of approved drugs with evident AChE inhibition capacity can 
hopefully guarantee the efficacy of new compounds, at least for targeting AChE, reducing the 
failure risk of developing new drugs. Combining the pharmacophores of AChEI drugs and 
BACE-1 inhibitors with a suitable linker is a common approach to design novel dual inhibitors 
targeting both enzymes. 
Zhu and co-workers [26] reported a series of hybrid compounds with AChE and BACE-1 dual 
inhibitions, and the scaffold was fused through three types of linkers with AChEI donepezil (1) 
and isophthalamide (26), a widely used pharmacophore in BACE-1 inhibitors [27]. Among these 
compounds, hybrid 27 (Figure 3) was considered as the most potential multi-target agent for 
therapeutic application of AD, and showed excellent dual inhibition in enzyme inhibitory potency 
assay (IC50 = 1.83 μM for AChE, IC50 = 0.567 μM for BACE-1), good inhibitory effects on Aβ 
production in APP-transfected HEK293 cells (IC50 = 98.7 nM), and a mild antioxidative effect 
against H2O2-induced PC12 cell injury at 10 μM. Further in vivo experiments in APP transgenic 
mice showed that compound 27 caused a 29% reduction in Aβ1-40 production through 
intracerebroventricular administration. Another compound, hybrid 28 (Figure 3), reported by the 
Praveen group [28], was fused with donepezil (1) and 2,4-disubstituted pyrimidine, a template 
with an Aβ-aggregation inhibition profile [29], and showed dual inhibitory activities in the enzyme 
assay (IC50 = 9.9 μM for AChE, 34% inhibition at 10 μM for BACE-1), 17.4% self-induced Aβ1-40 
aggregation inhibition at 100 μM, and 81.0% neuroblastoma cell viability at 40 μM.  
Fernandez-Bachiller and co-workers [30] reported a new family of AChEI tacrine (4) and 
4-oxo-4H-chromene (29) hybrids, in which the tacrine (4) scaffold was selected for AChE 
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inhibition and a flavonoid fragment derived from 4-oxo-4H-chromene (29) was chosen for 
BACE-1 inhibition. The most promising compound, hybrid 30 (Figure 3), showed potent dual 
inhibition against human AChE and BACE-1 (IC50 = 8.0 nM for AChE, IC50 = 2.8 μM for 
BACE-1), 1.3-fold more potent antioxidant activity than trolox (a vitamin E analogue), and good 
central nervous system (CNS) permeability in the parallel artificial membrane permeation assay 
for blood-brain barrier (PAMPA-BBB). A promising compound, hybrid 34 (Figure 3), reported by 
the Munoz-Torrero group [31], was fused through a long alkylamine linker with rhein (33) and 
huprine Y (32), another hybrid from tacrine (4) and huperzine A (31) [32], and showed potent 
inhibitory activities against human AChE and BACE-1 (IC50 = 3.6 nM for AChE, IC50 = 120 nM 
for BACE-1) and 47.9% Aβ42 anti-aggregating activity at 10 μM. Further in vivo experiments in 
APP-PS1 transgenic mice showed a central soluble Aβ-lowering effect four weeks later after 
intraperitoneal administration with compound 34. Replacement of the chlorobenzene ring of the 
huprine Y (32) moiety of 34 with pyridine led to lower AChE and BACE-1 inhibitory activities 
but potent antioxidant activity [33]. Another potent tacrine (4)-benzofuran (35) hybrid 36 (Figure 
3), reported by the Bartolini group [34], showed an interesting profile as a dual inhibitor against 
human AChE and BACE-1 (IC50 = 0.86 nM for AChE, IC50 = 1.35 μM for BACE-1) and 61.3% 
inhibition toward self-induced Aβ aggregation at 10 μM. Further in vivo studies confirmed that 36 
caused cognitive improvement in scopolamine-treated ICR mice and exhibited no significant 
hepatotoxicity. 
Computer-aided structure-based design is a practical and efficient method to find new active 
hits. Dominguez and co-workers [35] reported that after two cycles of design and screening of 
candidates based on pharmacophores and required interactions with the targets, compound 37 
(Figure 3) was discovered, synthesized, and showed evident dual inhibition activities against 
AChE and BACE-1 (IC50 = 9.1 μM for AChE, IC50 = 2.5 μM for BACE-1). Innovating new 
compound scaffolds through the self-accumulated effort and knowledge of scientific groups is 
another classical drug discovery approach. Belluti and co-workers [36] reported that compound 38 
(Figure 3) with a benzophenone core, showed dual-target inhibitory potency against human AChE 
and BACE-1 (IC50 = 1.57 μM for AChE, 10.72% inhibition at 3.38 μM for BACE-1). Recently, a 
new compound 39 (Figure 3) with a benzophenone core was reported by the Gabr group [37], 
showing potent human AChE and BACE-1 inhibition (IC50 = 4.11 nM for AChE, IC50 = 18.3 nM 
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for BACE-1), potential metal chelating capability, low toxicity toward SH-SY5Y neuroblastoma 
cells, and the ability to permeate the BBB tested by PAMPA. 
Figure 3. AChE and BACE-1 multi-target strategy 
 
2.2.1. GSK-3β 
The tau protein hypothesis is based on intracellular neurofibrillary tangles (NFTs) in the brain 
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which is another histopathological hallmark of AD just as senile plaques. NFTs are composed of 
paired helical filaments and straight filaments which are mainly caused by hyperphosphorylated 
tau protein [38]. The primary physiological function of tau protein, the most abundant 
microtubule-associated protein expressed in neurons, is to form microtubules with microtubule 
proteins, maintain microtubules stabilization, and promote microtubules to concentrate in clusters. 
When tau protein is hyperphosphorylated by the highly conserved threonine-serine kinase GSK-3β, 
primarily at Ser396, Ser199, and Ser413 [39], from the original 2-3 phosphate groups to 5-9 
phosphate groups, it is separated from microtubules and subsequently aggregated into insoluble 
NFTs which ultimately cause cell death [40]. Not only can GSK-3β phosphorylate tau protein, 
increased GSK-3β levels could regulate γ-secretase to induce Aβ formation in a unique way, 
resulting in toxicity to cultured neurons [41]. The three aspects of therapies based on the tau 
protein hypothesis include inhibiting the phosphorylation, preventing the aggregation of tau 
protein, and stabilizing microtubules, and GSK-3β is the major and specific target in the upstream 
tau pathway, making it the most popular target for small molecule compounds. The GSK-3β 
inhibitor tideglusib (10) (Figure 2) from AMO-pharma belongs to the thiadiazolidinone family and 
is currently in Phase II clinical trials for the treatment of myotonic dystrophy (MD). Tideglusib 
(10) was in Phase II clinical trials for the treatment of AD, but the trial was discontinued in 2012 
due to a lack of drug efficacy, even though it showed positive trends in four out of five clinical 
scales and induced a significantly benign response on the Mini-Mental State Examination (MMSE) 
[42]. 
2.2.2. AChE and GSK-3β multi-target strategy 
AChE and GSK-3β, each of which has been frequently adopted in multi-target strategies, are 
two vital AD-related targets in ACh concentration modulation and tau protein phosphorylation, 
respectively. However multi-target-directed ligands (MTDLs) possessing inhibitory potency for 
both enzymes are rarely reported. 
Hui and co-workers [43] reported that hybrid 41 (Figure 4), fused with the AChEI tacrine (4) 
and phenothiazine which is the key pharmacophore of the tau aggregation inhibitor methylene 
blue (40) (Figure 4), showed AChE inhibitory potency (IC50 = 89 nM). And tau 
hyperphosphorylation induced by okadaic acid in N2α cells was markedly prevented by hybrid 41 
with 39.5% down-regulation of the tau protein level when 41 was tested at 100 μM. After initial 
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ADME properties screening using PreADMET (v2.0), molecular docking studies were undertaken 
using Molegro Virtual Docker 2009 to test the inhibition potency of AChE and GSK-3β among 26 
hybrids, and 41 had significant affinity toward AChE, with a MolDock score of -183.585 kJ/mol, 
and toward GSK-3β, with a MolDock score of -148.821 kJ/mol. However, enzyme inhibitory 
activity of compound 41 against GSK-3β was not reported.  
Jiang and co-workers [44] reported a novel series of hybrids, fused with tacrine (4) and 
compound 42 (GSK-3β inhibitor, IC50 = 1.1 nM) which was reported by the Sivaprakasam group 
[45]. The most promising hybrid 43 (Figure 3) showed important human AChE and GSK-3β 
dual-target inhibitory activity (IC50 = 6.5 nM for AChE, IC50 = 66 nM for GSK-3β), good 
performance on Aβ self-aggregation with a 46% inhibitory rate at 20 μM, inhibition of tau protein 
hyperphosphorylation in mouse neuroblastoma N2α-Tau cells, less hepatotoxicity, and significant 
in vivo cognitive improvement in scopolamine-treated ICR mice. 
 
 
Figure 4. AChE and GSK-3β multi-target strategy 
 
2.3.1. MAOs 
  MAOs are metabolic enzymes that exist in two isoforms, MAO-A and MAO-B, distinguished 
by their difference on specificity of substrates and inhibitors [46]. MAOs can catalyze the 
oxidative deamination reactions of various biogenic and xenobiotic amines and play an important 
role in neurodegenerative diseases, such as AD and Parkinson disease (PD). The bioactivity of 
MAO-B is significantly increased in the cerebral cortex and the hippocampus regions of AD 
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patients, representing more than 80% of the total MAOs activity in the brain [47], and the activity 
and gene expression of MAO-A are also up-regulated in different brain areas [48]. High levels of 
MAOs catalyze oxidative deamination and increase the production of hydrogen peroxide and 
reactive oxygen species (ROS) which are responsible for oxidative injuries and the toxic 
environment characteristics of neurodegeneration [49], and the increased MAO-B levels can 
enhance astrogliosis in the brain [50]. MAO-A inhibitors are used in the clinic to treat anxiety and 
depression, which are also common symptoms considered to be risk factors in AD progression 
[51], while MAO-B inhibitors are used in the treatment of PD [52]. MAOs inhibitors can increase 
monoaminergic neurotransmission, decrease ROS formation and oxidative stress, and exert 
pharmacological effects including antioxidation, neuroprotection and cognitive improvement [53], 
which are potentially valuable for the treatment of AD. Rasagiline (11) from Teva pharma (Figure 
2) is a potent and irreversible selective MAO-B inhibitor approved in 2005 for the treatment of PD 
and has been in Phase II clinical trials for the treatment of AD. 
2.3.2. AChE and MAOs multi-target strategy 
  Ladostigil (44) from Avraham pharma (Figure 5) is currently in Phase II clinical trials for the 
treatment of mild cognitive impairment (MCI) and Alzheimer’s type dementia [54]. This drug 
shows inhibitory activities against AChE, BChE, MAO-A, and MAO-B in the brain [55], which is 
combined with the carbamate moiety of the cholinesterases (ChEs) inhibitor rivastigmine (3) and 
the indolamine moiety of the MAO-B inhibitor rasagiline (11).  
In multi-target strategies involving targets AChE and MAOs for AD therapies, donepezil 
(1)-related derivatives and tacrine (4)-related derivatives as MTDLs are still popular. The Unzeta 
group [56] reported a promising compound, hybrid 46 (Figure 5), which was fused with the 
benzylpiperidine moiety of donepezil (1) and the indolyl propargylamino moiety of the MAOs 
inhibitor 45 [57] (IC50 = 100 nM for MAO-A, IC50 = 63 nM for MAO-B) (Figure 5), that showed 
multi-target inhibitory potency against AChE, BChE, MAO-A, and MAO-B (IC50 = 0.35 μM for 
AChE, IC50 = 0.46 μM for BChE, IC50 = 5.2 nM for MAO-A, IC50 = 43 nM for MAO-B) and 
presented significant profiles with 47.8% self-induced Aβ aggregation inhibition at 10 μM and 
32.4% AChE-induced Aβ aggregation inhibition at 100 μM. Afterwards, the same group [58] 
reported that hybrid 48 (Figure 5), with the juxtaposition structure of donepezil (1) and M30 (47) 
which is potent brain-selective MAOs inhibitor and neuroprotective biometal-chelator [59] (IC50 = 
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57 nM for MAO-A, IC50 = 1.5 μM for MAO-B) (Figure 5), was a mixed-type ChEs inhibitor and 
an irreversible MAOs inhibitor with metal-chelating properties (IC50 = 1.8 μM for AChE, IC50 = 
1.6 μM for BChE, IC50 = 6.2 μM for MAO-A, IC50 = 10.2 μM for MAO-B), and was capable of 
significantly decreasing scopolamine-induced learning deficits in healthy adult mice. Later, the 
same group [60] reported another compound, hybrid 49 (Figure 5), which was an improved 
analogue of 48 and exhibited excellent ChEs inhibition potency, selective MAO-A inhibition (IC50 
= 29 nM for AChE, IC50 = 39 nM for BChE, IC50 = 10.1 μM for MAO-A), strong metal chelating 
capacity to Cu2+ and Zn2+ ions, and moderate antioxidant properties. Estrada and co-workers [61] 
reported that hybrid 51 (Figure 5), fused with donepezil (1) and the natural antioxidant cinnamic 
acid (50) (Figure 5), was ChEs and MAOs dual inhibitors (IC50 = 1.75 μM for AChE, IC50 = 0.69 
μM for BChE, IC50 = 3.5 μM for MAO-A, IC50 = 6.0 μM for MAO-B) and was able to improve 
the differentiation of adult subgranular zone (SGZ)-derived neural stem cells into a neuronal 
phenotype in vitro, thus showing antioxidant, cholinergic, neuroprotective and neurogenic 
properties. Hybrid 53 (Figure 5) reported by the Sang group [52] was fused with donepezil (1) and 
the notable MAO-B inhibitor 52 (IC50 = 2.9 nM) [62], and showed the potent and balanced 
inhibitory activities against ChEs and MAOs (IC50 = 0.56 μM for AChE, IC50 = 2.3 μM for BChE, 
IC50 = 0.3 μM for MAO-A, IC50 = 1.4 μM for MAO-B). Further investigation confirmed that 53 
could cross the BBB in vitro and abided by Lipinski’s rule of five. 
The Li group [63] reported that hybrid 55 (Figure 5), fused with the AChEI tacrine (4) and 
selegiline (54) which is an MAO-B inhibitor approved in 1981 for the treatment of PD, provided a 
good balance of activities toward ChEs and MAOs (IC50 = 22.6 nM for AChE, IC50 = 9.37 nM for 
BChE, IC50 = 0.37 μM for MAO-A, IC50 = 0.18 μM for MAO-B). The same group [64] reported 
that hybrid 57 (Figure 5), fused with tacrine (4) and the homoisoflavonoid compound 56 which is 
known as an efficient MAO-B selective inhibitor [65] (IC50 = 1.06 μM for MAO-B) (Figure 5), 
showed potent inhibitions against ChEs and MAO-B (IC50 = 67.9 nM for AChE, IC50 = 33.0 nM 
for BChE, IC50 = 0.401 μM for MAO-B). Later, the same group [66] reported another 
homoisoflavonoid derivative 58 (Figure 5), which showed the desired balance of AChE and 
MAO-B inhibitory activities (IC50 = 3.94 μM for AChE, IC50 = 3.44 μM for MAO-B). 
  Indolotacrine analogue 59 (Figure 5) reported by the Musilek group [67], was a potent inhibitor 




Figure 5. AChE and MAOs multi-target strategy 
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BChE, IC50 = 0.49 μM for MAO-A, IC50 = 53.9 μM for MAO-B), while its profiles of cytotoxicity 
in the CHO-K1 cell line (IC50 = 5.5 μM) and hepatotoxicity in the HepG2 cell line (IC50 = 1.22 
μM) were not sufficiently good, which was tested by MTT assay, respectively. The Li group [53, 
68] reported two series of propargylamine-modified pyrimidinylthiourea derivatives, among 
which compound 60 (Figure 5) was the best compound in the first series with good selective 
inhibitory activity against AChE and MAO-B (IC50 = 0.324 μM for AChE, IC50 = 1.427 μM for 
MAO-B), and demonstrated mild antioxidant ability, good copper chelating ability, and the ability 
to ameliorate scopolamine-induced cognitive impairment in mice. While compound 61 (Figure 5) 
was the most promising compound in the second series with a dual functional profile of targeting 
AChE and MAO-B (IC50 = 32 nM for AChE, IC50 = 2.117 μM for MAO-B), and showed 
antioxidant ability, good copper chelating capacity in vitro, and the ability to alleviate 
scopolamine-induced cognitive impairment in mice. 
2.4.1. Metal ions in the brain 
  Bioinorganic chemistry is a significant concept in therapeutic and diagnostic medicine, and the 
antitumor drug cisplatin (cis-[Pt(NH3)2Cl2]), a profound prototype in the bioinorganic field, is still 
a widely used chemotherapeutic agent for cancer and improves the survival rates of patients 
worldwide [69]. Potential bioinorganic chemical agents are metal ions, active metal complexes, 
and biometal chelators, which are most often used to limit the adverse effects of metal ions 
overload, inhibit selected metalloenzymes, or facilitate metal ions redistribution [69]. Excess metal 
levels in the brain are associated with peptide aggregation and oxidative stress, ultimately leading 
to cell death, and are responsible for neurodegenerative disorders, such as AD, PD, 
Creutzfeldt-Jakob disease, and amyotrophic lateral sclerosis [70]. High levels and dysregulation of 
Cu2+, Fe2+, Zn2+, and Ca2+, which are the four most important biometal ions [71], are closely 
implicated in the pathogenesis of AD. Cu2+ and Zn2+ have been shown to induce the generation of 
toxic Aβ oligomers by binding to Aβ peptides and influencing the Aβ aggregation pathway [72], 
while the redox-active metals, Cu(I/II) and Fe(II/III), have been demonstrated to generate 
cytotoxic ROS and cause neuronal damage [73]. Thus, biometal chelators which can 
down-regulate the high levels of biometals might be a potential therapeutic strategy for the 
treatment of AD. The approved antifungal drug clioquinol (12) (Figure 2), a moderate metal 
chelator with 8-hydroxyquinoline as a scaffold, was shown to extract metals from extracellular Aβ 
18 
 
aggregates and shift them to copper-carrier proteins in parenchymal cells without perturbing the 
overall essential metal biochemistry in the brain in recent Phase II clinical trials [74]. PBT-2 (13) 
from Prana Biotechnology (Figure 2) is a second-generation derivative of clioquinol (12), another 
metal chelator with an 8-hydroxyquinoline scaffold, and has been in Phase II clinical trials for the 
treatment of AD [75]. 
2.4.2. AChE and metal ions multi-target strategy  
  Fernandez-Bachiller and co-workers [76] reported that hybrid 62 (Figure 6), fused with the 
AChEI tacrine (4) and the metal chelator drug clioquinol (12), showed potent human AChE 
inhibitory activity (IC50 = 5.5 nM) and Cu2+ ion chelating ability based on UV-vis spectrometry. 
The maximum absorption at 242 nm of 62 in Tris buffer suffered a redshift to 248 nm with the 
addition of CuSO4, indicating the formation of complex 62-Cu(II). Hybrid 64 (Figure 6) reported 
by the Kong group [77] is fused with tacrine (4) and a naturally occurring compound flavone (63), 
and exhibited a significant ability to inhibit AChE (IC50 = 0.13 μM), along with Cu2+ and Fe2+ ions 
chelating ability tested by UV-vis spectrometry with wavelength ranging from 200 to 500 nm, 
79.1% self-induced Aβ aggregation inhibition at 20 μM, and low toxicity in SH-SY5Y 
neuroblastoma cells. Xie and co-workers [78] reported that a novel hybrid 66 (Figure 6), fused 
with tacrine (4) and coumarin (65) which is a natural product possessing AChE inhibitory activity 
[79], displayed the ability to inhibit AChE (IC50 = 92 nM), chelate Cu2+ and Fe2+ ions, and inhibit 
67.8% self-induced Aβ aggregation at 20 μM. UV-vis spectrometry with wavelength ranging from 
200 to 500 nm was used to test the metal chelating effect of 66, and the increased absorbance of 
66 along with increasing Cu2+ or Fe2+ concentrations indicated the occuring interactions between 
66 and these metals.  
Compound 67 (Figure 6) with a chromone scaffold reported by the Deng group [80] showed 
excellent inhibitory potency against rat AChE (IC50 = 70 nM), selective biometal chelating ability 
with Cu2+ via UV-vis spectrometry, moderate antioxidative activity, 59.2% self-induced Aβ 
aggregation inhibition at 25 μM, and 48.3% Cu2+-induced Aβ aggregation inhibition at 25 μM. The 
electronic spectra of compound 67 were recorded when the salts CuCl2, FeSO4, ZnCl2, or AlCl3 
were added, and the curve had a redshift (the peak at 340 nm shifted to 420 nm) with the addition 
of CuCl2, whereas no significant shift was observed with the other salts, suggesting the formation 
of complex 67-Cu(II). The Li group [72] reported a series of non-fused and non-assembly 
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pyrimidinylthiourea derivatives by screening hits from 630 compounds. Compound 68 (Figure 6) 
was the most promising compound which exhibited potent AChE inhibition (IC50 = 0.204 μM), 
specific Cu2+-chelating ability with the maximum absorption dramatically decreased at 290 nm in 
the UV-vis spectroscopy assay, antioxidant effects, regulatory function toward Cu2+-induced Aβ 
aggregation, low cytotoxicity, and moderate neuroprotection to human neuroblastoma SH-SY5Y  
 




cells. Further experiments showed appropriate BBB permeability of 68 both in vitro and in vivo, 
and memory and cognitive function improvement in scopolamine-induced amnesia mice after the 
administration of compound 68. Yan and co-workers [81] reported that a novel compound, hybrid 
70 (Figure 6), fused with the AChEI donepezil (1) and curcumin (69) which is extracted from the 
rhizome of Curcuma longa L., showed potent AChE inhibition (IC50 = 0.187 μM), metal-chelating 
ability with Cu2+ and Fe2+ via UV-vis spectrometry, 45.3% Aβ self-aggregation inhibition at 20 μM, 
and a remarkable antioxidant effect. 
2.5.1. NMDA receptor 
  The glutamatergic hypothesis of AD is based on the NMDA receptor which plays a crucial role 
in modifying major forms of synaptic plasticity, certain types of learning and memory formation, 
and consolidation of short-term memory into long-term memory under physiological conditions 
[82], and the states that appropriate inhibition toward NMDA receptor would ameliorate overall 
condition of AD patients. The NMDA receptor is a type of ionotropic glutamate receptor 
composed of two NR1 subunits and two NR2 (NR2A-D) subunits or occasionally NR3 subunit, 
and can be activated when bound with the excitatory neurotransmitter glutamate or the modulatory 
agent glycine (Gly). The NMDA receptor exerts important bio-functions in normal synaptic 
transmission, meaning it cannot be totally antagonized, whereas glutamate-related excitotoxicity 
and cell death could be caused when NMDA receptors are overstimulated by excess glutamate 
[83]. An optimal balance of NMDA receptors between glutamate stimulation and 
glutamate-related excitotoxicity is crucial to achieve the ideal treatment of AD.  
Memantine (14) (Table 1) (Figure 2) from Merz Pharma is a noncompetitive antagonist with a 
relatively low to moderate affinity toward NMDA receptor. Memantine (14) was approved in 2002 
and is the only NMDA receptor antagonist drug used in the clinic for the treatment of AD, while it 
still cannot prevent neuronal loss, stop deterioration of dementia, or reverse the disease 
progression of AD. Memantine (14) was formulated as tablets with four dose forms (5, 10, 15, 20 
mg) and an oral solution (10 mg/mL) in the European Union, whereas lower doses of tablet forms 
(5, 10 mg) and a more dilute oral solution (2 mg/mL) in the USA were licensed a year later. It is 
well absorbed by oral administration with nearly 100% bioavailability, it undergoes partial hepatic 
metabolism with a half-life of 60-100 h, and 48% of the administered drug is excreted as the 
original with unchanged structure in the urine [14]. Riluzole (15) (Figure 2) from Covis Pharma is 
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a sodium channel blocker approved in 1996 for the treatment of amyotrophic lateral sclerosis 
(ALS), is currently in Phase II clinical trials for mild AD and has exhibited a cognitive 
improvement effect. Riluzole (15) can lower extracellular glutamate levels, inhibit presynaptic 
glutamate release, and enhance glutamate transporter activity [2], suggesting a new clinically 
applicable therapeutic approach for AD. The withdrawn antihistamine drug dimebon (16) (Figure 
2), an NMDA receptor antagonist with the ability to bind AChE and NMDA receptor, was 
evaluated by Pfizer in Phase III clinical trials for the treatment of moderate to severe AD, but 
negative results were announced, and the development of dimebon (16) was discontinued [55]. 
2.5.2. AChE and NMDA receptor multi-target strategy 
  Cholinergic and glutamatergic neuronal systems influence each other through their joint 
dysfunction, and cholinergic deficits and glutamate-related excitotoxicity are central to AD 
pathology [84]. Excessive activation of NMDA receptor is implicated in the degenerative process 
of cholinergic neurons in AD, with the instance that neuronal decline caused by direct injection of 
NMDA into the rat basal forebrain generates reduced activity of choline acetyltransferase in the 
cortex [85]. Thus, the AChE and NMDA receptor multi-target strategy can affect the cholinergic 
and glutamatergic systems and is becoming an important idea because NMDA receptor 
antagonists can confront neurodegeneration and AChEIs can recover memory and cognition. 
Namzaric from Allergan approved in 2015 for the treatment of AD is a once-daily fixed-dose 
combination drug and comprised of memantine (14) hydrochloride and donepezil (1) 
hydrochloride, under the consideration of reducing pill burden and alleviating administration. In 
addition, caregivers can sprinkle the drug into food for patients who have difficulty in swallowing. 
  The Rosini group [86] has done much work to develop novel compounds with dual AChE and 
NMDA receptor inhibitory potency for potential treatment of AD. Hybrid 72 (Figure 7), named 
carbacrine, was fused with AChEI tacrine (4) and carbazole (71), and showed dual inhibitory 
activity against AChE and NMDA receptor (IC50 = 2.15 nM for AChE, IC50 = 0.74 μM for 
NR1/NR2A), 36.0% self-induced Aβ aggregation inhibition, 57.7% AChE-induced Aβ 
aggregation inhibition, and the ability to reduce oxidative stress [87]. Later, compound 73 (Figure 
7), named memagal, was reported as a novel hybrid formed by linking the AChEI galantamine (2) 
and the NMDA receptor antagonist drug memantine (14) [88]. Memagal (73) showed remarkably 
inhibitory potency against AChE (IC50 = 1.16 nM), and NMDA receptor inhibition which was 
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tested by a [3H] MK-801 binding assay (Ki = 4.6 μM, the value was derived from an iterative 
curve-fitting procedure). Further investigation revealed that hybrid 73 possessed NR2B-containing 
NMDA receptor inhibition based on a [3H] ifenprodil binding assay (Ki = 4.6 μM, the value was 
derived from an iterative curve-fitting procedure) and could inhibit NMDA (500 μM) mediated  
 
Figure 7. AChE and NMDA receptor multi-target strategy 
 
neurotoxicity in SH-SY5Y cell viability assay (IC50 = 0.28 nM), showing a highly potent 
neuroprotective effect. Dimebon (16) (Figure 7) has a multi-target profile for AD, while the 
activity against AChE and NMDA receptor is weak (IC50 = 42 μM for AChE, IC50 = 10-70 μM for 
NMDA receptor). In contrast, the optimized dimebon-derivative 74 (Figure 7) showed a potent 
multi-target profile against both AChE and NMDA receptor (IC50 = 0.195 μM for AChE, IC50 = 
11.0 μM for NMDA receptor) and 67.0% self-induced Aβ aggregation inhibitory potency [89]. 
Another interesting compound, hybrid 76 (Figure 7), reported by Makhaeva and co-workers [90], 
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was fused with dimebon (16) and phenothiazine (75). And compound 76 showed dual BChE and 
NMDA receptor inhibition potency with IC50 = 0.52 μM for BChE, IC50 = 14.6 μM for NMDA 
receptor in a [3H] MK-801 binding assay, and IC50 = 13.4 μM for NMDA receptor in a [3H] 
ifenprodil binding assay. 
2.6.1. 5-HT receptors 
   The serotonergic neurotransmitter system has crucial physiological functions in emotion and 
depression, while it is implicated with the cholinergic system in cognitive function of 
neurodegenerative disease [91]. 5-HT, also named serotonin, is considered as an inhibitory 
neurotransmitter compared with the excitatory neurotransmitter glutamate, while 5-HT has the 
bio-function to generate feelings of well-being and happiness, suggesting that the concentration of 
5-HT should be increased and the serotonergic system should be enhanced in depressive disorder. 
Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and paroxetine, are primarily 
approved as antidepressant drugs with the ability to increase 5-HT concentration in the synaptic 
cleft by inhibiting neuronal reuptake of 5-HT, improving the emotional state of depressive patients. 
There are seven subtypes of 5-HT receptors (5-HT1 to 5-HT7 receptors), which are classified by 
their structural and functional characteristics. 5-HT1A, 5-HT4, 5-HT6, and 5-HT7 receptors in the 
brain are associated with learning and memory. 5-HT1A receptor plays a significant role in 
therapeutics for major depressive disorder [92], and both agonists and antagonists of this receptor 
could be potential therapies for AD. 5-HT4 receptor is involved in memory processes, and partial 
agonists of this receptor could be utilized to treat the cognitive symptoms of AD [93]. 5-HT6 
receptor is expressed primarily in the cortex and the hippocampus areas of the brain and is 
associated with learning and memory processes, and antagonists of this receptor would be 
beneficial for ameliorating AD symptoms. 
Lecozotan (17) (Figure 2) from Pfizer is an orally available, potent and selective 5-HT1A 
receptor antagonist in Phase II/III clinical trials for the treatment of AD. PRX-03140 (18) (Figure 
2) from Ology Bioservices is a 5-HT4 receptor partial agonist in Phase II clinical trials for the 
treatment of AD. Idalopirdine (19) (Figure 2) from Otsuka and Lundbeck is an orally available and 
selective 5-HT6 receptor antagonist with promising efficacy and safety data in Phase II trials, but it 
did not meet its primary efficacy endpoint and was discontinued in Phase III clinical trials [2]. 
Intepirdine (20) (Figure 2) from Axovant Sciences is another 5-HT6 receptor antagonist in Phase 
24 
 
III clinical trials for the treatment of mild-to-moderate AD, and Phase II data indicated that the 
treatment of intepirdine (20) in combination with AChEI donepezil (1) may improve cognitive 
function in mild-to-moderate AD patients [2]. 
2.6.2. AChE and 5-HT receptors multi-target strategy  
  The serotonergic and cholinergic systems have physiological and pathological interactions with 
each other. Brain functions mediated by 5-HT4 receptor require a synergistic effect from 
cholinergic neurotransmission [94], and activation of 5-HT4 receptor can enhance the release of 
Ach in the hippocampus [95]. 5-HT4 receptor agonists could promote the nonamyloidogenic 
cleavage of APP, forming neurotrophic human soluble amyloid precursor protein α (sAPP-α) 
fragments and decreasing Aβ secretion in primary neurons [96]. Meanwhile, 5-HT6 receptor 
antagonists are thought to have the ability to enhance cholinergic neurotransmission [97]. Thus, 
AChE and 5-HT receptors could act synergistically on cognitive deficits, Aβ-mediated damage, 
and unhealthy emotions, meaning a multi-target strategy targeting these two targets could lead to a 
potential treatment for AD. 
  RS67333 (77) (Figure 8) is a 5-HT4 receptor partial agonist and well-known for its precognitive 
effect, and showed a synergistic effect with AChEI donepezil (1) on memory performance in mice 
[98]. RS67333 (77) has the ability to down-regulate Aβ level by activating 5-HT4 receptor, 
directly inhibit human AChE, and the capacity to induce sAPP-α release, reducing amyloid plaque 
formation [99] (IC50 = 403 nM for AChE, Ki = 13 nM for 5-HT4 receptor, EC50 = 27.2 nM for 
sAPP-α release). The Dallemagne group [100] reported a further optimized compound 78 (Figure 
8), which had a multi-target profile with both AChE inhibitory effect and 5-HT4 receptor agonist 
activity (IC50 = 95.8 nM for AChE, Ki = 4.2 nM for 5-HT4 receptor). Interestingly, compound 78 
was more antagonistic than agonistic toward 5-HT4 receptor, and molecular modeling studies 
failed to explain the antagonist profile of compound 78. Later, the same group [101] reported that 
the hybrid 79 (Figure 8), named donecopride, which was fused with RS67333 (77) and donepezil 
(1), showed dual AChE inhibition and 5-HT4 receptor agonist activity (IC50 = 16 nM for AChE, Ki 
= 6.6 nM for 5-HT4 receptor). Donecopride (79) stimulated the nonamyloidogenic 5-HT4 
receptor-mediated cleavage of APP and had greater potency in promoting neurotrophic sAPP-α 
release (EC50 = 11.3 nM) compared with RS67333 (77) [99]. Donecopride (79), which presented 
profiles with promising druggability parameters, favorable bioavailability and low toxicity, 
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exhibited a precognitive effect with an improvement in memory performance observed at 0.3 and 
1 mg/kg of donecopride (79) administration via intraperitoneal injection in further in vivo studies. 
Hybrid 81 (Figure 8), reported by the Li group [102], was fused with the AChEI tacrine (4) and 
vilazodone (80) which is 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor for the 
treatment of major depressive disorder (Figure 8), and exhibited moderate ChEs inhibitory 
activities, 5-HT1A receptor agonist activity, and 5-HT reuptake inhibitory activity (IC50 = 1.72 μM 
for AChE, IC50 = 0.34 μM for BChE, EC50 = 0.36 nM for 5-HT1A receptor, IC50 = 20.42 nM for 
5-HT reuptake). Further investigation showed that compound 81 also possessed good BBB 




Figure 8. AChE and 5-HT receptors multi-target strategy 
 
2.7.1. Histamine receptors  
The histaminergic system is composed of histamine and its receptors, plays an important role in 
maintaining brain homeostasis function and higher brain functions in the CNS, and participates in 
smooth muscle contraction, dilatation of capillaries, gastric acid secretion, and inflammation in the 
periphery. Histamine is an endogenous biogenic amine distributed throughout the body that acts as 
a neurotransmitter in nervous centralis and a local mediator in the periphery, and has high 
concentrations in the lung, skin, and gastrointestinal tract, carrying out its physiological functions 
with histamine receptors [103]. Histamine receptors, which are also distributed throughout the 
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body, are G protein-coupled receptors with different bio-functions. There are four histamine 
receptor subtypes, which are H1 receptor, H2 receptor, H3 receptor, and H4 receptor. H1 receptor 
activation mainly promotes allergic symptoms in the periphery and antagonists against this 
receptor are typically anti-allergic drugs, such as loratadine, while H2 receptor activation primarily 
stimulates the secretion of gastric acid and antagonists against this receptor can be antiulcer drugs, 
such as ranitidine. The interesting H3 receptor is an antoreceptor and heteroreceptor, providing 
negative feedback on histaminergic system and inhibiting the release of other neurotransmitters 
when it is activated, and antagonists against this receptor could augment the release of histamine 
and other neurotransmitters. H4 receptor is the most recently discovered histamine receptor, found 
in immunocompetent cells, and the development of anti-inflammatory drugs based on H4 receptor 
is anticipated [103]. 
  ABT-288 (21) (Figure 2) from AbbVie is an H3 receptor antagonist in Phase II clinical trials for 
the treatment of mild-to-moderate AD, but its clinical efficacy is not sufficient [104]. GSK-239512 
(22) (Figure 2) from GlaxoSmithKline is an H3 receptor antagonist in Phase II clinical trials for 
the treatment of AD and was discontinued due to lack of improvement in memory test [105], 
suggesting that single H3 receptor antagonists are not sufficiently effective in treating cognitive 
dysfunction in AD patients. SUVN-G3031 (structure not disclosed) from Suven Life Sciences is 
an H3 receptor antagonist in Phase I clinical trials for the treatment of cognitive disorders 
associated with AD patients. 
2.7.2. AChE and H3 receptor multi-target strategy 
  H3 receptor is considered as a significant target in AD because its activation decreases the 
presynaptic release of ACh, and its blockade augments the presynaptic release of ACh and 
improves cholinergic neurotransmission in the cortex. Thus, a multi-target strategy involving 
AChE and H3 receptor may exert a synergistic effect on up-regulating synaptic levels of ACh, 
which is a potential approach for the treatment of AD, but studies exploring this strategy have 
rarely been reported. 
Huang and co-workers [106] reported a series of compounds with a quinoxaline scaffold that 
showed related inhibitory activities against AChE, H3 receptor, and BACE-1 targets. The structure 
of the compounds was first designed to fuse the BACE-1 inhibitor 82 (IC50 = 11 nM) with the 
AChEI compound 83, named BYYT-25 (IC50 = 50 nM), two compounds reported by the same 
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group. In addition, the dihydroquinazoline moiety of 82 and benzyl pyrrolidine fragment of 83 
were selected to assemble the scaffold of novel H3 receptor inhibitor. Then, a virtual database 
consisting of plentiful compounds with novel scaffolds was screened on a pharmacophore model 
of BACE-1 inhibitor and next filtered by a molecular docking model of AChEI, resulting in the 
selection of 17 quinoxaline derivatives. Among these compounds, hybrid 84 (Figure 9) showed the 
most promising profiles, with potent activity toward AChE, H3 receptor, and BACE-1 targets (IC50 
= 483 nM for AChE, IC50 = 280 nM for H3 receptor antagonism, IC50 = 189 nM for H3 receptor 
inverse agonism, 46.64% inhibition for BACE-1 at 20 μM) and high selectivity for H3 receptor 
over H1, H2 or H4 receptors. Further receptor-binding studies of hybrid 84 demonstrated that it 
could achieve several key interactions with AChE and BACE-1, suggesting that quinoxaline 
derivatives may be a potential therapeutic for AD. 
 
 
Figure 9. AChE and H3 receptor multi-target strategy 
 
2.8.1. PDEs 
  PDEs are enzymes with the ability to break phosphodiester bonds, and usually referred to cyclic 
nucleotide phosphodiesterases. They are a group of enzymes that can hydrolyze and degrade 
intracellular second messengers, such as cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP), thus playing a major role in cell signal transduction 
throughout the brain and the periphery [107]. PDEs are classified into eleven isoenzyme families, 
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from PDE1 to PDE11, of which most have several subtypes, contributing to in total 100 specific 
human PDEs according to the current estimation [108]. Among these families, PDE4, 7, and 8 are 
specific enzymes for cAMP hydrolysis, and PDE5, 6, and 9 are specific enzymes for cGMP 
hydrolysis. PDE1, 2, 3, 10, and 11 are dual-substrate enzymes that can hydrolyze both cAMP and 
cGMP [109]. PDEs with the ability to degrade second messengers are important regulators of 
signal transduction in neuroplasticity and neuroprotection, and thus, PDEs inhibitors with the 
capacity to up-regulate the concentrations of cAMP and cGMP are receiving increased attention as 
potential agents to treat cognitive decline in AD. In addition, the nitric oxide/soluble guanylyl 
cyclase/cGMP (NO/sGC/cGMP) signaling pathway plays a pivotal role in learning and memory 
by regulating synaptic transmission and synaptic plasticity in the hippocampus and the cerebral 
cortex [110], and PDEs inhibitors could have a positive effect on that pathway. 
Vinpocetine from Gedeon Richter is a PDE1 inhibitor for the treatment of dementia and 
cognitive disorders that was approved in 1980, but it was reported to be ineffective on cognitive 
impairment in AD patients [109]. Cilostazol from Otsuka Pharma is an oral PDE3 inhibitor for the 
improvement of various symptoms of chronic arterial obstruction and was originally launched in 
1988. Cilostazol was tested as a co-treatment with the AChEI donepezil (1) for patients with 
mild-to-moderate AD. Rolipram from the National Institute of Mental Health is a PDE4D inhibitor 
in Phase II clinical trials for the treatment of major depression and had beneficial effects in a 
hippocampal-dependent memory assay, confirming that PDE4D plays a crucial role in memory 
consolidation [111]. MK-0952 (23) (Figure 2) from Merck is a PDE4 inhibitor in Phase II clinical 
trials for the treatment of mild-to-moderate AD, but no recent report could be found. PF-04447943 
(24) (Figure 2) from Pfizer is a PDE9A inhibitor in Phase I clinical trials for the treatment of 
sickle cell disease and was tested in Phase II clinical trials for the treatment of mild-to-moderate 
AD, while it was discontinued in 2011 due to the absence of any effects on cognition. BI-409306 
(25) (Figure 2) from Boehringer Ingelheim, a PDE9A inhibitor in Phase II clinical trials for the 
treatment of schizophrenia, was evaluated in Phase II clinical trials for the treatment of cognitive 
impairment in AD patients, and it was discontinued because the efficacy endpoint was not met. 
2.8.2. AChE and PDEs multi-target strategy 
  PDEs have eleven isoenzyme families with extensive physiological functions, meaing PDEs 
could be drug targets in many signaling pathways. Whereas multi-target strategies involving 
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targets of AChE and PDEs are rarely reported, indicating that such potential therapies would need 
to be explored for the treatment of AD. As a special cGMP hydrolytic enzyme, PDE5 has only one 
hypotype, PDE5A, and is distributed in the hippocampus, cortex and cerebellum of the brain [112]. 
Tadalafil (85) (Figure 10) of Lilly Icos, a selective PDE5 inhibitor drug launched in 2003 for the 
treatment of erectile dysfunction (ED), was found that it has the ability to reverse cognitive 
impairment and improve learning and memory in J20 transgenic mouse model of AD [113]. 
 
Figure 10. AChE and PDEs multi-target strategy 
 
Repurposing or redeveloping existing drugs for new uses is an important drug discovery 
strategy with effective and quick characteristics. Through the screening of old drug library, the Li 
group [114] found that PDE5A inhibitor drug tadalafil (85) has certain AChE inhibitory potency 
(IC50 = 26.159 μM for AChE, IC50 = 4 nM for PDE5A1). The long half-life and safety of tadalafil 
(85) for the chronic treatments of ED and hypertension make it a good lead compound to discover 
dual-target inhibitors against AChE and PDE5, being a potential therapy for the treatment of AD. 
To further explore this synergistic therapeutic route, a series of novel tadalafil (85) derivatives, as 
the first-generation of dual-target inhibitors toward AChE and PDE5, were synthesized and 
biologically evaluated. The most promising compound 86 (Figure 10), fused with AChEI 
donepezil (1) and tadalafil (85), exhibited good inhibitory potency against both targets of AChE 
and PDE5 (IC50 = 32 nM for AChE, IC50 = 1.530 μM for PDE5A1), excellent selectivity among 
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relative enzymes (IC50 = 3.880 μM for BChE, IC50 > 100 μM for PDE2A1, PDE3A, PDE4D3, 
PDE6C, PDE7A and PDE9A2), and improved BBB penetrability. Further in vivo experiments 
showed that citrate of 86 could reverse the cognitive dysfunction in scopolamine-induced AD 
mice with comparable curative effect against donepezil (1), and had effect on enhancing cAMP 
response element-binding protein (CREB) phosphorylation, a crucial factor in memory formation 
and synaptic plasticity [115], by increasing cGMP levels, which may ameliorate the cognitive 
impairment and restore synaptic function in AD. 
 
3. Multi-target strategies without AChE 
Multi-target strategies are not limited to strategies involving AChE, and more diverse structures 
of hits could be designed based on the specific and multiple protein pockets of AD-associated 
targets. In the disease network of AD, several targets involving AChE or not, could implicated 
with others, and their respective signaling pathways could cross with others, contributing together 
to the development of AD progression. The importance of AChE in disease network is prominent, 
while the potential possibility among other targets should not be neglected for AD therapy. Thus, 
seeking the specific relationships in the disease network between targets without AChE is also a 
significant strategy for the treatment of AD. In this section, three multi-target strategies without 
AChE are demonstrated (Figure 1). 
3.1. BACE-1 and GSK-3β multi-target strategy  
   The histopathological hallmarks in the brain of AD patients are senile plaques and NFTs, and 
BACE-1 and GSK-3β are two key targets responsible for each pathological cascade, suggesting 
that a dual inhibitor against BACE-1 and GSK-3β could produce a downstream synergistic effect 
[116]. The Cavalli group [117] reported a series of triazinone derivatives as the first generation of 
dual BACE-1 and GSK-3β inhibitors, which were derived from a cyclic amide group and a 
guanidine moiety under the guidance of a fragment-based approach. Among these derivatives 
possessing balanced micromolar affinities for both BACE-1 and GSK-3β, compound 87 (Figure 
11) showed the most promising profiles, with the best balanced inhibitory potency against 
BACE-1 and GSK-3β (IC50 = 18.03 μM for BACE-1, IC50 = 14.67 μM for GSK-3β), effective 
neuroprotective and neurogenic activities due to the modulation of GSK-3β and simultaneous 
inhibition toward both targets, and no sign of neurotoxicity in glial and neuronal cells. Further in 
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vivo investigation in mice indicated that compound 87 displayed good drug-like properties in oral 
bioavailability (66%) and BBB penetration (a brain concentration of 0.62 μM of compound 87 
was observed 30 min later when a very low dose of 3 mg/kg was administered with compound 87). 
The Belluti group [118] reported another series of dual inhibitors targeting BACE-1 and GSK-3β 
that showed good neuroprotective and pharmacokinetic properties. This series of inhibitors was 
based on the natural product curcumin (69) which possesses efficacy and safety for both 
prevention and treatment of various disorders [119]. In this study, the curcumin derivative 
compound 88 (Figure 11) had the most balanced concurrent inhibitory activity against BACE-1 
and GSK-3β (IC50 = 0.97 μM for BACE-1, IC50 = 0.90 μM for GSK-3β), exerted neuroprotective 
activity by inducing the NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme, possessed a weak 
antioxidant effect, and showed brain permeability, making it a promising drug candidate. 
 
 
Figure 11. BACE-1 and GSK-3β multi-target strategy 
3.2. MAO-B and metal ions multi-target strategy  
The Li group [120] reported that a series of novel hybrids fused with the main pharmacophores 
of selegiline (54), an MAO-B inhibitor (IC50 = 18.5 nM) approved in 1981 for the treatment of PD, 
and clioquinol (12), a moderate metal chelator approved as an antifungal drug, showed MAO-B 
inhibitory potency, antioxidant activity, biometal chelating ability, and effective inhibition against 
Cu(II)-induced Aβ aggregation. The most promising compound 89 (Figure 12) exhibited good 
inhibitory activity against MAO-B (IC50 = 0.21 μM for MAO-B), good antioxidant activity 
(oxygen radical absorbance capacity (ORAC) = 4.2), and the ability to permeate the BBB in a 
PAMPA-BBB study. UV-vis spectrometry was used to investigate the metal-chelating ability of 
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compound 89, and the results indicated that it could interact with Cu2+, Fe2+, and Zn2+ metal ions, 
especially with Cu2+ion. The maximum absorption peak at 236 nm of the solution of compound 89 
was obviously decreased and another absorption peak at 276 nm suffered a redshift to 282 nm 
after CuSO4 was added to the solution, while the specific absorption peaks at 236 nm and 276 nm 
shifted slightly after FeSO4 or ZnCl2 was added to the solution, respectively, suggesting that 
compound 89 possess the biometal chelating ability. These results indicated that compound 89 had 
the potential profiles to be a good multi-target and multifunctional agent for the treatment of AD. 
 
 
Figure 12. MAO-B and metal ions multi-target strategy 
3.3. PDEs and metal ions multi-target strategy  
  Down-regulation of the NO/sGC/cGMP pathway and impaired homeostasis of biometals play 
significant and malignant roles in AD, suggesting that PDEs inhibition and metal chelation would 
have synergistic therapeutic effect and a multi-target strategy involving PDEs and metal chelating 
is possible. 
  Su and co-workers [121] reported that a novel hybrid 90 (Figure 13), fused with the PDE9A 
inhibitor PF-04447943 (24) (Figure 2) and clioquinol (12) which is a moderate metal chelator 
approved as an antifungal drug, showed inhibitory potency against PDE9 (IC50 = 34 nM) with 
high selectivity over other PDEs (55-fold), notable Cu2+-induced Aβ aggregation inhibition, and 
favorable BBB permeability. Hybrid 90 also had remarkable metal-chelating capacity toward 
metal ions Cu2+, Fe2+, and Zn2+, tested by UV-vis spectrophotometry. The absorption peaks at 259 
nm of the solution of compound 90 suffered a redshift to 273 nm after incubation of compound 90 
with Cu2+, and similar results were obtained upon incubation of compound 90 with Fe2+ and Zn2+. 
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These results indicated that hybrid 90 could be a promising compound for the treatment of AD. A 
novel series of hybrids, reported by the Li group [122], were fused with the pharmacophores of the 
moderate metal chelator clioquinol (12) and the PDE4D inhibitor moracin M (91) (IC50 = 2.91 μM) 
which is a natural product isolated from the root bark of Morus alba Linn with antioxidant and 
anti-inflammatory activities. The most promising compound, hybrid 92 (Figure 13), had good 
profiles with excellent PDE4D inhibitory potency (IC50 = 0.32 μM), significant antioxidant effects, 
appropriate biometal chelating functions toward the metal ions Cu2+, Fe2+, and Zn2+ according to a 
UV-vis spectroscopy assay, and the ability to modulate self-induced Aβ aggregation and 
Cu2+-induced Aβ aggregation. 
 
 
Figure 13. PDEs and metal ions multi-target strategy 
 
4. Conclusion 
Currently, AD is an incurable disease with a complicated disease network and brings enormous 
suffering to patients and their families. Therefore, there is an urgent need to be met for the society. 
Huge efforts have been made by research groups worldwide to conquer this disease, and lots of 
AD-related targets have been found with the attempt to solve the puzzle caused by the disease 
network. Nine major targets were discussed in this overview, among which AChE demonstrates a 
significant influence on this field, and corresponding single-target drugs or candidates (25 
instances) were exhibited. Moreover, the therapies based on other targets, such as cyclooxygenase 
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(COX) and 5-lipoxygenase (5-LOX) [123] which are not discussed here, can also be considered as 
potential targets for the possible treatment of AD. There are also some NCEs, with multifunction 
effects and overall cognitive improvement on AD-related animal models, not discussed here in 
detail because their corresponding binding-targets have not been clearly figured out. But these 
NCEs have showed enough and excellent curative effect to be drug candidates for the treatment of 
AD. For example, mecripyrine (SCR1693) of Yene Pharma, an AChE inhibitor which was 
developed based on multi-target design strategy, could remarkably attenuate tau 
hyperphosphorylation and improve memory deficits, and preserve dendrite morphologies as well 
as spine density [124]. It is in the Phase I clinical trials in China for the potential treatment of AD 
[125]. 
Considering the intricate pathogenesis of AD and the shortcomings of single-target drugs, we 
think the multi-target design strategies are the frontier scientific research for potential treatment of 
AD because efficient and synergetic modulation toward several targets could be realized by 
multi-target inhibitors to better affect the disease network and control AD progression than 
single-target drugs. Eleven multi-target design strategies were discussed in this overview and 
various promising compounds (42 instances) for the potential treatment of AD were presented. It 
is deficient for current situation that existing scaffolds are still not sufficient to enrich the 
compound libraries for AD treatment, and most designed compounds with dual-target activities 
are hybrids of known structures or drugs. Nevertheless, natural products [126] and computer-aided 
drug design could be beneficial and promising to explore novel scaffolds and structures with a 
better curative effect. More efforts are needed to make the multi-target compounds eventually 
developed into new drugs which could be successfully used in the clinic as ideal AD treatments. 
 
Acknowledgements 
The authors thank the National Natural Science Foundation of China (No. 81874289) for 
financial support. This study was financed in part by the "Double First-Class" University project 
CPU2018GY04, China Pharmaceutical University. 
 
References 
[1] K. Blennow, M.J. de Leon, H. Zetterberg, Alzheimer's disease, Lancet 368 (2006) 387-403. 
35 
 
[2] S.Y. Hung, W.M. Fu, Drug candidates in clinical trials for Alzheimer's disease, J. Biomed. Sci. 24 (2017) 47. 
[3] A. Alzheimer, Uber eine eigenartige Erkrankung der Hirnrinde, Allg. Z. Psychiatr. 64 (1907) 146-148. 
[4] M.G. Ulep, S.K. Saraon, S. McLea, Alzheimer disease, J. Nurse. Pract. 14 (2018) 129-135. 
[5] C.A. Lane, J. Hardy, J.M. Schott, Alzheimer's disease, Eur. J. Neurol. 25 (2018) 59-70. 
[6] P. Davies, A.J. Maloney, Selective loss of central cholinergic neurons in Alzheimer’s disease, Lancet 308 (1976) 
1403-1403. 
[7] A.V. Terry, J.J. Buccafusco, The cholinergic hypothesis of age and Alzheimer's disease-related cognitive 
deficits: Recent challenges and their implications for novel drug development, J. Pharmacol. Exp. Ther. 306 (2003) 
821-827. 
[8] K.B. Augustinsson, D. Nachmansohn, Distinction between acetylcholine-esterase and other choline 
ester-splitting enzymes, Science 110 (1949) 98-99. 
[9] T.H. Ferreira-Vieira, I.M. Guimaraes, F.R. Silva, F.M. Ribeiro, Alzheimer's disease: targeting the cholinergic 
system, Curr. Neuropharmacol. 14 (2016) 101-115. 
[10] N.H. Greig, T. Utsuki, Q.S. Yu, X.X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, D.K. Lahiri, A new 
therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase, Curr. Med. Res. Opin. 17 
(2001) 159-165. 
[11] E. Giacobini, Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's 
disease?, Drugs Aging 18 (2001) 891-898. 
[12] S. Kumar, Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin, Indian J. 
Pharmacol. 47 (2015) 444-446. 
[13] A. Kumar, A. Singh, Ekavali, A review on Alzheimer's disease pathophysiology and its management: an 
update, Pharmacol. Rep. 67 (2015) 195-203. 
[14] F. Zemek, L. Drtinova, E. Nepovimova, V. Sepsova, J. Korabecny, J. Klimes, K. Kuca, Outcomes of 
Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine, Expert. Opin. Drug Saf. 13 (2014) 
759-774. 
[15] L. Ismaili, B. Refouvelet, M. Benchekroun, S. Brogi, M. Brindisi, S. Gemma, G. Campiani, S. Filipic, D. 
Agbaba, G. Esteban, M. Unzeta, K. Nikolic, S. Butini, J. Marco-Contelles, Multitarget compounds bearing tacrine- 
and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease, Prog. 
Neurobiol. 151 (2017) 4-34. 
[16] J.A. Hardy, G.A. Higgins, Alzheimer’s disease: the amyloid cascade hypothesis, Science. 256 (1992) 184-185. 
36 
 
[17] J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to 
therapeutics, Science 297 (2002) 353-356. 
[18] D.J. Selkoe, J. Hardy, The amyloid hypothesis of Alzheimer's disease at 25 years, EMBO. Mol. Med. 8 (2016) 
595-608. 
[19] W.V. Graham, A. Bonito-Oliva, T.P. Sakmar, Update on Alzheimer's disease therapy and prevention strategies, 
Annu. Rev. Med. 68 (2017) 413-430. 
[20] J. Kim, L. Onstead, S. Randle, R. Price, L. Smithson, C. Zwizinski, D.W. Dickson, T. Golde, E. McGowan, 
Aβ40 inhibits amyloid deposition in vivo, J. Neurosci. 27 (2007) 627-633. 
[21] P. Scheltens, K. Blennow, M.M.B. Breteler, B. de Strooper, G.B. Frisoni, S. Salloway, W.M. Van der Flier, 
Alzheimer's disease, Lancet 388 (2016) 505-517. 
[22] Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, P. Denis, W. Fan, H. Kha, J.H. Zhang, Y.H. Gong, L. 
Martin, J.C. Louis, Q. Yan, W.G. Richards, M. Citron, R. Vassar, Mice deficient in BACE1, the Alzheimer's 
β-secretase, have normal phenotype and abolished β-amyloid generation, Nat. Neurosci. 4 (2001) 231-232. 
[23] M.E. Kennedy, A.W. Stamford, X. Chen, K. Cox, J.N. Cumming, M.F. Dockendorf, M. Egan, L. Ereshefsky, 
R.A. Hodgson, L.A. Hyde, S. Jhee, H.J. Kleijn, R. Kuvelkar, W. Li, B.A. Mattson, H. Mei, J. Palcza, J.D. Scott, M. 
Tanen, M.D. Troyer, J.L. Tseng, J.A. Stone, E.M. Parker, M.S. Forman, The BACE1 inhibitor verubecestat 
(MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients, Sci. Transl. Med. 8 
(2016) 363ra150. 
[24] N. Hawkes, Merck ends trial of potential Alzheimer's drug verubecestat, BMJ. 356 (2017) j845. 
[25] A. Satlin, T. Fukushima, Composition comprising an anti-Aβ protofibril antibody and Aβ-secretase BACE1 
inhibitor for the treatment of alzheimer’s disease, WO 2018/081460 A1. (2018) 
[26] Y.P. Zhu, K. Xiao, L.P. Ma, B. Xiong, Y. Fu, H.P. Yu, W. Wang, X. Wang, D.Y. Hu, H.L. Peng, J.Y. Li, Q. 
Gong, Q. Chai, X.C. Tang, H.Y. Zhang, J. Li, J.K. Shen, Design, synthesis and biological evaluation of novel dual 
inhibitors of acetylcholinesterase and β-secretase, Bioorg. Med. Chem. 17 (2009) 1600-1613. 
[27] S.J. Stachel, C.A. Coburn, T.G. Steele, K.G. Jones, E.F. Loutzenhiser, A.R. Gregro, H.A. Rajapakse, M.T. Lai, 
M.C. Crouthamel, M. Xu, K. Tugusheva, J.E. Lineberger, B.L. Pietrak, A.S. Espeseth, X.P. Shi, E. Chen-Dodson, 
M.K. Holloway, S. Munshi, A.J. Simon, L. Kuo, J.P. Vacca, Structure-based design of potent and selective 
cell-permeable inhibitors of human β-secretase (BACE-1), J. Med. Chem. 47 (2004) 6447-6450. 
[28] T. Mohamed, J.C.K. Yeung, M.S. Vasefi, M.A. Beazely, P.P.N. Rao, Development and evaluation of 
multifunctional agents for potential treatment of Alzheimer's disease: Application to a pyrimidine-2,4-diamine 
37 
 
template, Bioorg. Med. Chem. Lett. 22 (2012) 4707-4712. 
[29] T. Mohamed, X.B. Zhao, L.K. Habib, J.R. Yang, P.P.N. Rao, Design, synthesis and structure-activity 
relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and 
Aβ-aggregation inhibitors, Bioorg. Med. Chem. 19 (2011) 2269-2281. 
[30] M.I. Fernandez-Bachiller, C. Perez, L. Monjas, J. Rademann, M.I. Rodriguez-Franco, New 
tacrine-4-Oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with 
cholinergic, antioxidant, and β-amyloid-reducing properties, J. Med. Chem. 55 (2012) 1303-1317. 
[31] E. Viayna, I. Sola, M. Bartolini, A. De Simone, C. Tapia-Rojas, F.G. Serrano, R. Sabate, J. Juarez-Jimenez, B. 
Perez, F.J. Luque, V. Andrisano, M.V. Clos, N.C. Inestrosa, D. Munoz-Torrero, Synthesis and multitarget 
biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents, J. Med. 
Chem. 57 (2014) 2549-2567. 
[32] P. Camps, R. El Achab, J. Morral, D. Munoz-Torrero, A. Badia, J.E. Banos, N.M. Vivas, X. Barril, M. Orozco, 
F.J. Luque, New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors 
of interest for the treatment of Alzheimer's disease, J. Med. Chem. 43 (2000) 4657-4666. 
[33] F.J. Perez-Areales, N. Betari, A. Viayna, C. Pont, A. Espargaro, M. Bartolini, A. De Simone, J.F.R. Alvarenga, 
B. Perez, R. Sabate, R.M. Lamuela-Raventos, V. Andrisano, F.J. Luque, D. Munoz-Torrero, Design, synthesis and 
multitarget biological profiling of second-generation anti-Alzheimer rhein-huprine hybrids, Future Med. Chem. 9 
(2017) 965-981. 
[34] X.M. Zha, D. Lamba, L.L. Zhang, Y.H. Lou, C.X. Xu, D. Kang, L. Chen, Y.G. Xu, L.Y. Zhang, A. De Simone, 
S. Samez, A. Pesaresi, J. Stojan, M.G. Lopez, J. Egea, V. Andrisano, M. Bartolini, Novel tacrine-benzofuran 
hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: design, synthesis, biological 
evaluation, and X-ray crystallography, J. Med. Chem. 59 (2016) 114-131. 
[35] J.L. Dominguez, F. Fernandez-Nieto, M. Castro, M. Catto, M.R. Paleo, S. Porto, F.J. Sardina, J.M. Brea, A. 
Carotti, M.C. Villaverde, F. Sussman, Computer-aided structure-based design of multitarget leads for Alzheimer's 
disease, J. Chem. Inf. Model. 55 (2015) 135-148. 
[36] F. Belluti, A. De Simone, A. Tarozzi, M. Bartolini, A. Djemil, A. Bisi, S. Gobbi, S. Montanari, A. Cavalli, V. 
Andrisano, G. Bottegoni, A. Rampa, Fluorinated benzophenone derivatives: Balanced multipotent agents for 
Alzheimer's disease, Eur. J. Med. Chem. 78 (2014) 157-166. 
[37] M.T. Gabr, M.S. Abdel-Raziq, Design and synthesis of donepezil analogues as dual AChE and BACE-1 
inhibitors, Bioorg. Chem. 80 (2018) 245-252. 
38 
 
[38] F. Panza, V. Solfrizzi, D. Seripa, B.P. Imbimbo, M. Lozupone, A. Santamato, C. Zecca, M.R. Barulli, A. 
Bellomo, A. Pilotto, A. Daniele, A. Greco, G. Logroscino, Tau-centric targets and drugs in clinical development for 
the treatment of Alzheimer's disease, Biomed. Res. Int. (2016) 3245935. 
[39] J. Avila, F. Wandosell, F. Hernandez, Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis 
and glycogen synthase kinase-3 inhibitors, Expert. Rev. Neurother. 10 (2010) 703-710. 
[40] M. Iba, J.L. Guo, J.D. McBride, B. Zhang, J.Q. Trojanowski, V.M.Y. Lee, Synthetic tau fibrils mediate 
transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy, J. Neurosci. 33 
(2013) 1024-1037. 
[41] C.J. Phiel, C.A. Wilson, V.M.Y. Lee, P.S. Klein, GSK-3α regulates production of Alzheimer's disease 
amyloid-β peptides, Nature 423 (2003) 435-439. 
[42] T. del Ser, K.C. Steinwachs, H.J. Gertz, M.V. Andres, B. Gomez-Carrillo, M. Medina, J.A. Vericat, P. 
Redondo, D. Fleet, T. Leon, Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study, J. 
Alzheimers Dis. 33 (2013) 205-215. 
[43] A.L. Hui, Y. Chen, S.J. Zhu, C.S. Gan, J. Pan, A. Zhou, Design and synthesis of tacrine-phenothiazine hybrids 
as multitarget drugs for Alzheimer's disease, Med. Chem. Res. 23 (2014) 3546-3557. 
[44] X.Y. Jiang, T.K. Chen, J.T. Zhou, S.Y. He, H.Y. Yang, Y. Chen, W. Qu, F. Feng, H.P. Sun, Dual GSK-3β/AChE 
inhibitors as a new strategy for multitargeting anti-Alzheimer's disease drug discovery, ACS. Med. Chem. Lett. 9 
(2018) 171-176. 
[45] P. Sivaprakasam, X. Han, R.L. Civiello, S. Jacutin-Porte, K. Kish, M. Pokross, H.A. Lewis, N. Ahmed, N. 
Szapiel, J.A. Newitt, E.T. Baldwin, H. Xiao, C.M. Krause, H. Park, M. Nophsker, J.S. Lippy, C.R. Burton, D.R. 
Langley, J.E. Macor, G.M. Dubowchik, Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure 
guided in-depth exploration of chemical space around a pyrrolopyridinone core, Bioorg. Med. Chem. Lett. 25 
(2015) 1856-1863. 
[46] J.P. Johnston, Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. 
Pharmacol. 17 (1968) 1285-1297. 
[47] J. Hirvonen, M. Kailajarvi, T. Haltia, S. Koskimies, K. Nagren, P. Virsu, V. Oikonen, H. Sipila, P. Ruokoniemi, 
K. Virtanen, M. Scheinin, J.O. Rinne, Assessment of MAO-B occupancy in the brain with PET and 
[C-11]-L-Deprenyl-D-2: a dose-finding study with a novel MAO-B Inhibitor, EVT 301, Clin. Pharmacol. Ther. 85 
(2009) 506-512. 
[48] M. Naoi, P. Riederer, W. Maruyama, Modulation of monoamine oxidase (MAO) expression in 
39 
 
neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression, J. Neural. 
Transm. (Vienna) 123 (2016) 91-106. 
[49] M.B.H. Youdim, Y.S. Bakhle, Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and 
depressive illness, Br. J. Pharmacol. 147 (2006) S287-S296. 
[50] P. Riederer, W. Danielczyk, E. Grunblatt, Monoamine oxidase-B inhibition in Alzheimer's disease, 
Neurotoxicology 25 (2004) 271-277. 
[51] F. Caraci, A. Copani, F. Nicoletti, F. Drago, Depression and Alzheimer's disease: neurobiological links and 
common pharmacological targets, Eur. J. Pharmacol. 626 (2010) 64-71. 
[52] Z.P. Sang, W.L. Pan, K.R. Wang, Q.G. Ma, L.T. Yu, W.M. Liu, Design, synthesis and biological evaluation of 
3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase 
inhibitors for the treatment of Alzheimer's disease, Bioorg. Med. Chem. 25 (2017) 3006-3017. 
[53] Y.X. Xu, J. Zhang, H. Wang, F. Mao, K.T. Bao, W.W. Liu, J. Zhu, X.K. Li, H.Y. Zhang, J. Li, Rational Design 
of novel selective dual-target inhibitors of acetylcholinesterase and monoamine oxidase B as potential 
anti-Alzheimer’s disease agents, ACS. Chem. Neurosci. 10 (2019) 482-496. 
[54] O. Weinreb, T. Amit, O. Bar-Am, M.B.H. Youdim, Neuroprotective effects of multifaceted hybrid agents 
targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease, Br. J. Pharmacol. 173 (2016) 
2080-2094. 
[55] M. Rosini, E. Simoni, R. Caporaso, A. Minarini, Multitarget strategies in Alzheimer's disease: benefits and 
challenges on the road to therapeutics, Future Med. Chem. 8 (2016) 697-711. 
[56] I. Bolea, J. Juarez-Jimenez, C. de los Rios, M. Chioua, R. Pouplana, F.J. Luque, M. Unzeta, J. 
Marco-Contelles, A. Samadi, Synthesis, biological evaluation, and molecular modeling of donepezil and 
N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent 
cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease, J. Med. Chem. 54 (2011) 
8251-8270. 
[57] V. Perez, J.L. Marco, E. Fernandez-Alvarez, M. Unzeta, Relevance of benzyloxy group in 2-indolyl 
methylamines in the selective MAO-B inhibition, Br. J. Pharmacol. 127 (1999) 869-876. 
[58] L. Wang, G. Esteban, M. Ojima, O.M. Bautista-Aguilera, T. Inokuchi, I. Moraleda, I. Iriepa, A. Samadi, 
M.B.H. Youdim, A. Romero, E. Soriano, R. Herrero, A.P.F. Fernandez, Ricardo-Martinez-Murillo, J. 
Marco-Contelles, M. Unzeta, Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional 
metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease, Eur. J. Med. Chem. 
40 
 
80 (2014) 543-561. 
[59] Y. Avramovich-Tirosh, T. Amit, O. Bar-Am, H.L. Zheng, M. Fridkin, M.B.H. Youdim, Therapeutic targets and 
potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for 
the treatment of Alzheimer's disease, J. Neurochem. 100 (2007) 490-502. 
[60] M.Y. Wu, G. Esteban, S. Brogi, M. Shionoya, L. Wang, G. Campiani, M. Unzeta, T. Inokuchi, S. Butini, J. 
Marco-Contelles, Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological 
evaluation, Eur. J. Med. Chem. 121 (2016) 864-879. 
[61] M. Estrada, C. Herrera-Arozamena, C. Perez, D. Vina, A. Romero, J.A. Morales-Garcia, A. Perez-Castillo, 
M.I. Rodriguez-Franco, New cinnamic - N-benzylpiperidine and cinnamic - N,N-dibenzyl(N-methyl)amine 
hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic 
properties, Eur. J. Med. Chem. 121 (2016) 376-386. 
[62] S. Carradori, R. Silvestri, New frontiers in selective human MAO-B inhibitors, J. Med. Chem. 58 (2015) 
6717-6732. 
[63] C.J. Lu, Q. Zhou, J. Yan, Z.Y. Du, L. Huang, X.S. Li, A novel series of tacrine-selegiline hybrids with 
cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease, Eur. J. Med. 
Chem. 62 (2013) 745-753. 
[64] Y. Sun, J.W. Chen, X.M. Chen, L. Huang, X.S. Li, Inhibition of cholinesterase and monoamine oxidase-B 
activity by Tacrine-Homoisoflavonoid hybrids, Bioorg. Med. Chem. 21 (2013) 7406-7417. 
[65] N. Desideri, A. Bolasco, R. Fioravanti, L.P. Monaco, F. Orallo, M. Yanez, F. Ortuso, S. Acaro, 
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties, J. Med. 
Chem. 54 (2011) 2155-2164. 
[66] Y.L. Wang, Y. Sun, Y.Y. Guo, Z.C. Wang, L. Huang, X.S. Li, Dual functional cholinesterase and MAO 
inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of 
homoisoflavonoid derivatives, J. Enzyme Inhib. Med. Chem. 31 (2016) 389-397. 
[67] O. Benek, O. Soukup, M. Pasdiorova, L. Hroch, V. Sepsova, P. Jost, M. Hrabinova, D. Jun, K. Kuca, D. Zala, 
R.R. Ramsay, J. Marco-Contelles, K. Musilek, Design, Synthesis and in vitro evaluation of indolotacrine 
analogues as multitarget-directed ligands for the treatment of Alzheimer's disease, ChemMedChem. 11 (2016) 
1264-1269. 
[68] Y.X. Xu, H. Wang, X.K. Li, S.N. Dong, W.W. Liu, Q. Gong, T.D. Wang, Y. Tang, J. Zhu, J. Li, H.Y. Zhang, F. 
Mao, Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea 
41 
 
derivatives as multifunctional agents for the treatment of Alzheimer's disease, Eur. J. Med. Chem. 143 (2018) 
33-47. 
[69] T. Storr, K.H. Thompson, C. Orvig, Design of targeting ligands in medicinal inorganic chemistry, Chem. Soc. 
Rev. 35 (2006) 534-544. 
[70] K.J. Barnham, C.L. Masters, A.I. Bush, Neurodegenerative diseases and oxidative stress, Nat. Rev. Drug 
Discov. 3 (2004) 205-214. 
[71] K.P. Kepp, Bioinorganic chemistry of Alzheimer's disease, Chem. Rev. 112 (2012) 5193-5239. 
[72] X.K. Li, H. Wang, Z.Y. Lu, X.Y. Zheng, W. Ni, J. Zhu, Y. Fu, F.L. Lian, N.X. Zhang, J. Li, H.Y. Zhang, F. 
Mao, Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents, J. Med. 
Chem. 59 (2016) 8326-8344. 
[73] N. Braidy, A. Poljak, C. Marjo, H. Rutlidge, A. Rich, T. Jayasena, N.C. Inestrosa, P. Sachdev, Metal and 
complementary molecular bioimaging in Alzheimer's disease, Front. Aging Neurosci. 6 (2014) 138. 
[74] Z.R. Wang, J.H. Hu, X.P. Yang, X. Feng, X.S. Li, L. Huang, A.S.C. Chan, Design, synthesis, and evaluation of 
orally bioavailable quinoline-indole derivatives as innovative multitarget-directed ligands: promotion of cell 
proliferation in the adult murine hippocampus for the treatment of Alzheimer's disease, J. Med. Chem. 61 (2018) 
1871-1894. 
[75] P.J. Crouch, K.J. Barnham, Therapeutic redistribution of metal ions to treat Alzheimer's disease, Acc. Chem. 
Res. 45 (2012) 1604-1611. 
[76] M.I. Fernandez-Bachiller, C. Perez, G.C. Gonzalez-Munoz, S. Conde, M.G. Lopez, M. Villarroya, A.G. 
Garcia, M.I. Rodriguez-Franco, Novel tacrine-8-Hydroxyquinoline hybrids as multifunctional agents for the 
treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties, 
J. Med. Chem. 53 (2010) 4927-4937. 
[77] S.Y. Li, X.B. Wang, S.S. Xie, N. Jiang, K.D.G. Wang, H.Q. Yao, H.B. Sun, L.Y. Kong, Multifunctional tacrine 
flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of 
Alzheimer's disease, Eur. J. Med. Chem. 69 (2013) 632-646. 
[78] S.S. Xie, X.B. Wang, J.Y. Li, L. Yang, L.Y. Kong, Design, synthesis and evaluation of novel tacrine coumarin 
hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease, Eur. J. Med. Chem. 64 (2013) 
540-553. 
[79] C. Bruhlmann, F. Ooms, P.A. Carrupt, B. Testa, M. Catto, F. Leonetti, C. Altomare, A. Carotti, Coumarins 




[80] Q. Liu, X.M. Qiang, Y. Li, Z.P. Sang, Y.X. Li, Z.H. Tan, Y. Deng, Design, synthesis and evaluation of 
chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease, 
Bioorg. Med. Chem. 23 (2015) 911-923. 
[81] J. Yan, J.H. Hu, A.Q. Liu, L. He, X.S. Li, H. Wei, Design, synthesis, and evaluation of multitarget-directed 
ligands against Alzheimer's disease based on the fusion of donepezil and curcumin, Bioorg. Med. Chem. 25 (2017) 
2946-2955. 
[82] E. Shimizu, Y.P. Tang, C. Rampon, J.Z. Tsien, NMDA receptor-dependent synaptic reinforcement as a crucial 
process for memory consolidation, Science 290 (2000) 1170-1174. 
[83] H. Geerts, G. Grossberg, Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors 
for combination therapy in the treatment of Alzheimer's disease, J. Clin. Pharmacol. 46 (2006) 8S-16S. 
[84] C.G. Parsons, W. Danysz, A. Dekundy, I. Pulte, Memantine and cholinesterase inhibitors: complementary 
mechanisms in the treatment of Alzheimer's disease, Neurotox. Res. 24 (2013) 358-369. 
[85] G.L. Wenk, W. Danysz, S.L. Mobley, Investigations of neurotoxicity and neuroprotection within the nucleus 
basalis of the rat, Brain Res. 655 (1994) 7-11. 
[86] M. Rosini, E. Simoni, A. Minarini, C. Melchiorre, Multi-target design strategies in the context of Alzheimer's 
disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces, Neurochem. Res. 39 
(2014) 1914-1923. 
[87] M. Rosini, E. Simoni, M. Bartolini, A. Cavalli, L. Ceccarini, N. Pascu, D.W. McClymont, A. Tarozzi, M.L. 
Bolognesi, A. Minarini, V. Tumiatti, V. Andrisano, I.R. Mellor, C. Melchiorre, Inhibition of acetylcholinesterase, 
β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: A promising direction for the 
multi-target-directed ligands gold rush, J. Med. Chem. 51 (2008) 4381-4384. 
[88] E. Simoni, S. Daniele, G. Bottegoni, D. Pizzirani, M.L. Trincavelli, L. Goldoni, G. Tarozzo, A. Reggiani, C. 
Martini, D. Piomelli, C. Melchiorre, M. Rosini, A. Cavalli, Combining galantamine and memantine in 
multitargeted, new chemical entities potentially useful in Alzheimer's disease, J. Med. Chem. 55 (2012) 
9708-9721. 
[89] M. Rosini, E. Simoni, M. Bartolini, E. Soriano, J. Marco-Contelles, V. Andrisano, B. Monti, M. Windisch, B. 
Hutter-Paier, D.W. McClymont, I.R. Mellor, M.L. Bolognesi, The bivalent ligand approach as a tool for improving 
the in vitro anti-Alzheimer multitarget profile of dimebon, ChemMedChem. 8 (2013) 1276-1281. 
[90] G.F. Makhaeva, S.V. Lushchekina, N.P. Boltneva, V.B. Sokolov, V.V. Grigoriev, O.G. Serebryakova, E.A. 
43 
 
Vikhareva, A.Y. Aksinenko, G.E. Barreto, G. Aliev, S.O. Bachurin, Conjugates of γ-carbolines and phenothiazine 
as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease, Sci. 
Rep. 5 (2015) 13164. 
[91] J.J. Rodriguez, H.N. Noristani, A. Verkhratsky, The serotonergic system in ageing and Alzheimer's disease, 
Prog. Neurobiol. 99 (2012) 15-41. 
[92] J. Savitz, I. Lucki, W.C. Drevets, 5-HT1A receptor function in major depressive disorder, Prog. Neurobiol. 88 
(2009) 17-31. 
[93] A. Mowla, M. Mosavinasab, H. Haghshenas, A. Borhani-Haghighi, Does serotonin augmentation have any 
effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled 
clinical trial, J. Clin. Psychopharmacol. 27 (2007) 484-487. 
[94] M. Matsumoto, H. Togashi, K. Morio, K. Ueno, S. Ohashi, T. Kojima, M. Yoshioka, Evidence for 
involvement of central 5-HT4 receptors in cholinergic function associated with cognitive processes: behavioral, 
electrophysiological, and neurochemical studies, J. Pharmacol. Exp. Ther. 296 (2001) 676-682. 
[95] S. Cho, Y. Hu, Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal 
survival, Exp. Neurol. 203 (2007) 274-278. 
[96] F. Lezoualc'h, 5-HT4 receptor and Alzheimer's disease: The amyloid connection, Exp. Neurol. 205 (2007) 
325-329. 
[97] N. Upton, T.T. Chuang, A.J. Hunter, D.J. Virley, 5-HT6 receptor antagonists as novel cognitive enhancing 
agents for Alzheimer's disease, Neurotherapeutics 5 (2008) 458-469. 
[98] T. Freret, V. Bouet, A. Quiedeville, G. Nee, P. Dallemagne, C. Rochais, M. Boulouard, Synergistic effect of 
acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice, 
Behav. Brain Res. 230 (2012) 304-308. 
[99] C. Lecoutey, D. Hedoua, T. Freret, P. Giannoni, F. Gaven, M. Since, V. Bouet, C. Ballandonne, S. Corvaisier, 
A.M. Freon, S. Mignani, T. Cresteil, M. Boulouard, S. Claeysen, C. Rochais, P. Dallemagne, Design of 
donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for 
Alzheimer's disease treatment, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) E3825-E3830. 
[100] C. Lecoutey, C. Rochais, D. Genest, S. Butt-Gueulle, C. Ballandonne, S. Corvaisier, F. Dial, A. Lepailleur, 
J.S.D. Santos, P. Dallemagne, Synthesis of dual AChE/5-HT4 receptor multi-target directed ligands, 
Medchemcomm. 3 (2012) 627-634. 
[101] C. Rochais, C. Lecoutey, F. Gaven, P. Giannoni, K. Hamidouche, D. Hedou, E. Dubost, D. Genest, S. 
44 
 
Yahiaoui, T. Freret, V. Bouet, F. Dauphin, J.S.D. Santos, C. Ballandonne, S. Corvaisier, A. Malzert-Freon, R. Legay, 
M. Boulouard, S. Claeysen, P. Dallemagne, Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase 
(AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against 
Alzheimer's disease: the design of donecopride, J. Med. Chem. 58 (2015) 3172-3187. 
[102] W.W. Liu, H. Wang, X.K. Li, Y.X. Xu, J. Zhang, W. Wang, Q. Gong, X.X. Qiu, J. Zhu, F. Mao, H.Y. Zhang, J. 
Li, Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against 
depression with cognitive impairment, Bioorg. Med. Chem. 26 (2018) 3117-3125. 
[103] P. Panula, P.L. Chazot, M. Cowart, R. Gutzmer, R. Leurs, W.L.S. Liu, H. Stark, R.L. Thurmond, H.L. Haas, 
International union of basic and clinical pharmacology. XCVIII. Histamine receptors, Pharmacol. Rev. 67 (2015) 
601-655. 
[104] G.M. Haig, Y. Pritchett, A. Meier, A.A. Othman, C. Hall, L.M. Gault, R.A. Lenz, A randomized study of H3 
antagonist ABT-288 in mild-to-moderate Alzheimer's dementia, J. Alzheimers Dis. 42 (2014) 959-971. 
[105] M. Kubo, T. Kishi, S. Matsunaga, N. Iwata, Histamine H3 receptor antagonists for Alzheimer's disease: a 
systematic review and meta-analysis of randomized placebo-controlled trials, J. Alzheimers Dis. 48 (2015) 
667-671. 
[106] W.H. Huang, L. Tang, Y. Shi, S.F. Huang, L. Xu, R. Sheng, P. Wu, J. Li, N.M. Zhou, Y.Z. Hu, Searching for 
the multi-target-directed ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds 
with AChE, H3R and BACE 1 inhibitory activities, Bioorg. Med. Chem. 19 (2011) 7158-7167. 
[107] J.A. Beavo, Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms, Physiol. Rev. 
75 (1995) 725-748. 
[108] A.T. Bender, J.A. Beavo, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use, 
Pharmacol. Rev. 58 (2006) 488-520. 
[109] P.R.A. Heckman, C. Wouters, J. Prickaerts, Phosphodiesterase inhibitors as a target for cognition 
enhancement in aging and Alzheimer's disease: a translational overview, Curr. Pharm. Des. 21 (2015) 317-331. 
[110] Z.H. Qin, Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy, Future Med. Chem. 
5 (2013) 1451-1468. 
[111] Y.F. Li, Y.F. Cheng, Y. Huang, M. Conti, S.P. Wilson, J.M. O'Donnell, H.T. Zhang, Phosphodiesterase-4D 
knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis 
via increased cAMP signaling, J. Neurosci. 31 (2011) 172-183. 
[112] P.R.A. Heckman, A. Blokland, J. Ramaekers, J. Prickaerts, PDE and cognitive processing: beyond the 
45 
 
memory domain, Neurobiol. Learn. Mem. 119 (2015) 108-122. 
[113] C. Garcia-Barroso, A. Ricobaraza, M. Pascual-Lucas, N. Unceta, A.J. Rico, M.A. Goicolea, J. Salles, J.L. 
Lanciego, J. Oyarzabal, R. Franco, M. Cuadrado-Tejedor, A. Garcia-Osta, Tadalafil crosses the blood-brain barrier 
and reverses cognitive dysfunction in a mouse model of AD, Neuropharmacology 64 (2013) 114-123. 
[114] F. Mao, H. Wang, W. Ni, X. Zheng, M.J. Wang, K.T. Bao, D.Z. Ling, X.K. Li, Y.X. Xu, H.Y. Zhang, J. Li, 
Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of 
acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease, ACS. 
Chem. Neurosci. 9 (2018) 328-345. 
[115] S.H. Francis, M.A. Blount, J.D. Corbin, Mammalian cyclic nucleotide phosphodiesterases: molecular 
mechanisms and physiological functions, Physiol. Rev. 91 (2011) 651-690. 
[116] F. Prati, G. Bottegoni, M.L. Bolognesi, A. Cavalli, BACE-1 inhibitors: from recent single-target molecules to 
multitarget compounds for Alzheimer's disease, J. Med. Chem. 61 (2018) 619-637. 
[117] F. Prati, A. De Simone, P. Bisignano, A. Armirotti, M. Summa, D. Pizzirani, R. Scarpelli, D.I. Perez, V. 
Andrisano, A. Perez-Castillo, B. Monti, F. Massenzio, L. Polito, M. Racchi, A.D. Favia, G. Bottegoni, A. Martinez, 
M.L. Bolognesi, A. Cavalli, Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and 
GSK-3β inhibitors, Angew. Chem. Int. Ed. Engl. 54 (2015) 1578-1582. 
[118] R.M.C. Di Martino, A. De Simone, V. Andrisano, P. Bisignano, A. Bisi, S. Gobbi, A. Rampa, R. Fato, C. 
Bergamini, D.I. Perez, A. Martinez, G. Bottegoni, A. CavaIli, F. Belluti, Versatility of the curcumin scaffold: 
discovery of potent and balanced dual BACE-1 and GSK-3β inhibitors, J. Med. Chem. 59 (2016) 531-544. 
[119] S. Prasad, S.C. Gupta, A.K. Tyagi, B.B. Aggarwal, Curcumin, a component of golden spice: From bedside to 
bench and back, Biotechnol. Adv. 32 (2014) 1053-1064. 
[120] S.S. Xie, J. Chen, X.R. Li, T. Su, Y.L. Wang, Z.R. Wang, L. Huang, X.S. Li, Synthesis and evaluation of 
selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease, 
Bioorg. Med. Chem. 23 (2015) 3722-3729. 
[121] T. Su, T.H. Zhang, S.S. Xie, J. Yan, Y. Wu, X.S. Li, L. Huang, H.B. Luo, Discovery of novel PDE9 inhibitors 
capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer's disease, Sci. Rep. 6 
(2016) 21826. 
[122] Z.R. Wang, Y.L. Wang, B. Wang, W.R. Li, L. Huang, X.S. Li, Design, synthesis, and evaluation of orally 
available clioquinol-moracin M hybrids as multitarget-directed ligands for cognitive improvement in a rat model of 
neurodegeneration in Alzheimer's disease, J. Med. Chem. 58 (2015) 8616-8637. 
46 
 
[123] A.S. Cornec, L. Monti, J. Kovalevich, V. Makani, M.J. James, K.G. Vijayendran, K. Oukoloff, Y.M. Yao, 
V.M.Y. Lee, J.Q. Trojanowski, A.B. Smith, K.R. Brunden, C. Ballatore, Multitargeted imidazoles: potential 
therapeutic leads for Alzheimer's and other neurodegenerative diseases, J. Med. Chem. 60 (2017) 5120-5145. 
[124] Y. Xia, R. Liu, R. Chen, Q. Tian, K. Zeng, J. Hu, X. Liu, Q. Wang, P. Wang, X.C. Wang, J.Z. Wang. Novel 
multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and neuropathologies in rats, 
J. Alzheimers Dis. 42 (2014) 1029-1039. 
[125] http://www.chictr.org.cn/showproj.aspx?proj=27354&from=singlemessage&isappinstalled=0 
[126] H. Yao, J.K. Liu, S.T. Xu, Z.Y. Zhu, J.Y. Xu, The structural modification of natural products for novel drug 
discovery, Expert. Opin. Drug Discov. 12 (2017) 121-140. 
